MEDI6570
MEDI6570 is an antibody of the lectin-like oxidized low-density lipoprotein receptor-1 (LOX-1) that is being tested in people with type 2 diabetes to see if it reduces their risk of cardiovascular disease. The drug is developed by AstraZeneca.[1][2][3]
References
[edit]- ^ Lubrano, Valter; Balzan, Silvana; Papa, Angela (3 October 2023). "LOX-1 variants modulate the severity of cardiovascular disease: state of the art and future directions". Molecular and Cellular Biochemistry. doi:10.1007/s11010-023-04859-0.
- ^ Varma, Vijayalakshmi; Sinibaldi, Dominic; Ongstad, Emily L; Vavere, Andrea L; Gabrielsen, Anders; Schiopu, Alexandru; George, Richard T; Gan, Li-ming; Nilsson, Jan; Collen, Anna (8 November 2022). "Abstract 11971: Identification of Response Biomarkers and Signaling Pathways Associated With the LOX-1 Blockade by MEDI6570 in Type 2 Diabetes". Circulation. 146 (Suppl_1). doi:10.1161/circ.146.suppl_1.11971.
- ^ Vavere, Andrea L.; Sinsakul, Marvin; Ongstad, Emily L.; Yang, Ye; Varma, Vijayalakshmi; Jones, Christopher; Goodman, Joanne; Dubois, Vincent F. S.; Quartino, Angelica L.; Karathanasis, Sotirios K.; Abuhatzira, Liron; Collén, Anna; Antoniades, Charalambos; Koren, Michael J.; Gupta, Ruchi; George, Richard T. (7 February 2023). "Lectin‐Like Oxidized Low‐Density Lipoprotein Receptor 1 Inhibition in Type 2 Diabetes: Phase 1 Results". Journal of the American Heart Association. 12 (3). doi:10.1161/JAHA.122.027540. PMC 9973634.
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |